Quest PharmaTech Inc. focuses on developing novel therapeutics for targeted cancer treatment. While the company has a low market cap of $3.38M and a modest return on equity (ROE) of 3.1%, its current ratio of 0.07 raises liquidity concerns, indicating potential short-term financial challenges. Additionally, the low debt-to-equity ratio of 0.05 suggests a conservative leverage approach, which may be a strength. However, the stagnant stock price at $0.02 reflects market skepticism about growth prospects. Overall, the company shows potential but faces significant financial hurdles.
Loading financial metrics...
Company has $59K in cash but burned $32K last quarter. At this burn rate, only 1.9 quarters of runway remain without additional financing.
Company posted a loss of $-999K over the last year, representing Infinity% of revenue.
Debt of $1.0M is 16.9x the company's cash position of $59K.
No significant opportunities identified
Based on current financial metrics
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2025-Q2 (April 30, 2025)